Blog Post

AI Trends for 2022 - FDA Regulatory

MoFo Tech

16 Dec 2021

FDA is actively monitoring the use of AI and machine learning (ML) software in medical devices and clinical developments, and has taken a number of first steps in building out a regulatory framework.  In 2021, FDA published the AI and Machine Learning Software as a Medical Device Action Plan, which outlines FDA’s approach to regulating AI/ML technologies and next steps in furthering oversight, as well as the Good Machine Learning Practice for Medical Device Development: Guiding Principles, to inform the development of Good Machine Learning Practice.  FDA also released a database of AI/ML-enabled medical devices currently marketed in the United States and will update this list as FDA reviews and authorizes additional AI/ML-enabled medical devices going forward. 

Bethany Hills, Partner and Co-Chair of our MoFo FDA Regulatory and Compliance Practice outlines the AI trends for 2022 in our MoFo Tech blog. Read more.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.